Immune Function Marker Does Not Predict Benefit of Trastuzumab in HER-2+ Breast Cancer Patients
- Details
- Written by Paul Scotti
- Category: Health News
Jacksonville, Florida - A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker - the quantity of tumor-infiltrating lymphocytes (S-TILs) in a biopsy - appears irrelevant when trastuzumab is used.
Quality of Life at Diagnosis May Predict Survival for Patients With Aggressive Lymphoma
- Details
- Written by Joe Dangor
- Category: Health News
San Francisco, California - Self-reported quality of life among patients diagnosed with aggressive lymphoma can predict overall survival and event-free survival, a Mayo Clinic study has found. The results were presented at the 56th American Society of Hematology annual meeting, in San Francisco.
Strategic Author Sherrie Palm Raises Awareness for Women’s Pelvic Health
- Details
- Written by PRW
- Category: Health News
Mukwonago, Wisconsin - Sherrie Palm, author of the award-winning book "Pelvic Organ Prolapse: The Silent Epidemic", and the founder/executive director of APOPS, Association for Pelvic Organ Prolapse Support, a U.S.-based 501c3 nonprofit with international arms, is requesting contributions of any size to fund STIGMA*STRIDE Pennies for POP campaign.
FDA approves first test to confirm the presence of Human T-cell Lymphotropic Virus-I/II antibodies
- Details
- Written by IVN
- Category: Health News
Washington, DC - The U.S. Food and Drug Administration today approved MP Diagnostics HTLV Blot 2.4, the first FDA-licensed supplemental test for Human T-cell Lymphotropic Virus-I/II (HTLV-I/II). This test is intended for use as an additional, more specific test for human serum or plasma specimens that have previously tested positive on an FDA-licensed HTLV-I/II blood donor screening test. The MP Diagnostics HTLV Blot 2.4 is a qualitative enzyme immunoassay test intended to confirm infection with HTLV and to differentiate between HTLV-I and HTLV-II.
More than 16 million children live in states where they can buy e-cigarettes legally
- Details
- Written by CDC
- Category: Health News
Washington, DC - Forty states have enacted laws prohibiting the sale of electronic nicotine delivery systems (ENDS), including e-cigarettes, to minors, but 10 states and the District of Columbia still permit such sales, according to a report published by the Centers for Disease Control and Prevention in today’s Morbidity and Mortality Weekly Report (MMWR).
CDC’s Tips From Former Smokers campaign provided outstanding return on investment
- Details
- Written by IVN
- Category: Health News
Washington, DC - The 2012 Tips From Former Smokers campaign spent only $480 per smoker who quit and $393 per year of life saved, according to an analysis by the Centers for Disease Control and Prevention. The results of the study were published today in the American Journal of Preventive Medicine.
Page 3250 of 3785